Indications |
Oral Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Renal impairment: Dosage reduction may be required. Oral Patients with haemophilia undergoing dental extraction Adult: Initially, 6 g immediately after the procedure, followed by 6 g every 6 hr for up to 10 days. Intravenous Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g as a 2% solution over 1 hr followed by a 1 g/hr infusion continued for up to 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Renal impairment: Dosage reduction may be required. Special Populations: Dose reduction in patients with renal impairment. |
Contraindications |
Bleeding due to disseminated intravascular coagulation. Rapid IV administration. |
Warnings / Precautions |
Renal or cardiac disorders. Urinary tract bleeding, haematuria of upper urinary tract origin; veno-occlusive hepatic disease, skeletal myopathy, neonates. Monitor creatinine phosphokinase. Avoid admin with factor IX complex concentrates. Pregnancy and lactation. |
Adverse Reactions |
Oedema, headache, malaise, allergic and anaphylactic reactions, anaphylaxis, bradycardia, hypotension, peripheral ischaemia, thrombosis, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopaenia, thrombocytopaenia, increased CPK, muscle damage, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnoea, nasal congestion, pulmonary embolism, pruritus, rash, tinnitus, decreased vision, watery eyes, increased BUN, dry ejaculation. Potentially Fatal: Cardiac and hepatic damage. |
Overdose Reactions |
Symptoms may range from no reaction to transient hypotension or severe acute renal failure resulting in death. |
Drug Interactions |
Increased risk of hypercoagulability with OC and oestrogens. See Below for More aminocaproic acid Drug Interactions |
Mechanism of Actions |
Aminocaproic acid inhibits the action of plasminogen activators and, to a lesser extent, it also has some antiplasmin activity. Absorption: Absorbed readily from the GI tract (oral); peak plasma concentrations after 2 hr. Distribution: Distributed widely. Excretion: Via urine (as unchanged); 2 hr (elimination half-life). |
Administration |
May be taken with or without food. (May be taken w/ meals to prevent GI upset.) |
Storage Conditions |
Intravenous: Store at 15-30°C. |
ATC Classification |
B02AA01 - aminocaproic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage. |
Storage |
Intravenous: Store at 15-30°C. |
Available As |
|
Aminocaproic Acid
Post Review about Aminocaproic Acid Click here to cancel reply.
Aminocaproic Acid Containing Brands
Aminocaproic Acid is used in following diseases
Drug - Drug Interactions of Aminocaproic Acid
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.